» Articles » PMID: 27701923

Benign Thyroid Nodules Treatment Using Percutaneous Laser Ablation (PLA) and Radiofrequency Ablation (RFA)

Overview
Publisher Informa Healthcare
Specialties Oncology
Pharmacology
Date 2016 Oct 6
PMID 27701923
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To evaluate the reduction over time of benign thyroid nodules treated using percutaneous laser ablation (PLA) and radiofrequency ablation (RFA) by the same equipe.

Materials And Methods: Ninety patients (age 55.6 ± 14.1 years) underwent ablation for benign thyroid nodule causing compression/aesthetic dissatisfaction from 2011. Fifty-nine (age 55.8 ± 14.1 years) underwent RFA and 31 (age 55.2 ± 14.2 years) PLA, ultrasound guided. Technical success, complications, duration of ablation and treatment, energy deployed, volumetric percentage reduction at 1, 6 and 12 months were derived. A regression model for longitudinal measurements was used with random intercept and random slope. Values are expressed as mean ± standard deviation or N (%).

Results: Technical success was always obtained. No major complications occurred. Mean ablation time was 30.1 ± 13.8 vs. 13.9 ± 5.9 min (p < .0001) and mean energy deployment was 5422.3 ± 2484.5 J vs. 34 662.7 ± 15 812.3 J in PLA vs. RFA group. Mean volume reduced from 20.3 ± 16.4 ml to 13.17 ± 10.74 ml (42% ± 17% reduction) at 1st month, 8.7 ± 7.4 ml (60% ± 15% reduction) at 6th month and 7.1 ± 7.7 ml (70%% ± 16% reduction) at 12th month, in PLA group, and from 32.7 ± 19.5 ml to 17.2 ± 12.9 ml (51%±15% reduction) at 1st month, 12.8 ± 9.6 ml (64 ± 14% reduction) at 6th month and 9.9 ± 9.2 ml (74% ± 14% reduction) at 12th month in RFA group. No difference in time course of the relative volume reduction between the two techniques was found.

Conclusions: RFA and PLA are similarly feasible, safe and effective in treating benign thyroid nodules when performed by the same equipe. RFA is faster than PLA but require significantly higher energy.

Citing Articles

Preclinical testing of a new radiofrequency ablation device in a porcine perianal fistula model.

Yoon S, Choi J, Son Y, Lee H, Hong K Ann Coloproctol. 2025; 41(1):84-92.

PMID: 40044113 PMC: 11894940. DOI: 10.3393/ac.2024.00626.0089.


Efficacy and safety of radiofrequency ablation for secondary hyperparathyroidism: a systematic review and meta-analysis.

Li M, Jiang H, Wang Y, Li F Asian Biomed (Res Rev News). 2024; 18(6):287-296.

PMID: 39697216 PMC: 11650422. DOI: 10.2478/abm-2024-0036.


Diagnosing and management of thyroid nodules and goiter - current perspectives.

Studen K, Domagala B, Gaberscek S, Zaletel K, Hubalewska-Dydejczyk A Endocrine. 2024; 87(1):39-47.

PMID: 39217209 PMC: 11739261. DOI: 10.1007/s12020-024-04015-8.


Assessing the relative effectiveness of various ultrasound-guided ablation techniques for treating benign thyroid nodules: A systematic review and network meta-analysis.

Sun X, Chen J, Zou Y, Lei J, Liu W Medicine (Baltimore). 2024; 103(18):e38014.

PMID: 38701262 PMC: 11062690. DOI: 10.1097/MD.0000000000038014.


Model-Optimizing Radiofrequency Parameters of 3D Finite Element Analysis for Ablation of Benign Thyroid Nodules.

Bini F, Pica A, Marinozzi F, Giusti A, Leoncini A, Trimboli P Bioengineering (Basel). 2023; 10(10).

PMID: 37892940 PMC: 10604455. DOI: 10.3390/bioengineering10101210.